Dr. Alissa Jamie Cooper, MD

Dr. Cooper practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Cooper's NPI, 1609305614, was assigned on June 5, 2017. Dr. Cooper graduated from The Warren Alpert Medical School of Brown University in 2017. Dr. Cooper holds Massachusetts license 271366.

Dr. Cooper's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Cooper's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Cooper is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Cooper to 3 more hospitals and 6 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cooper practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Cooper's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Cooper is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Cooper's licenses on file in 3 states: Massachusetts, New Jersey and New York.

CMS data shows 400 Medicare services from Dr. Cooper across 3 procedure codes in 2024, for 129 Medicare patients. Medicare paid $38,829 for them.

CMS counts 129 Medicare patients who saw Dr. Cooper in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have cancer, and 75% have high blood pressure. 22% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cooper's median patient age at 71, with 59% women.

In 2024, Dr. Cooper wrote 375 Medicare Part D claims for 86 patients. 71% of them were for generic drugs. CMS names the drug for 213 of them, across 7 drugs with 11 or more claims each, at $1,337,417 in total drug cost. In 2023, CMS named 30 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Cooper for performance year 2024, reported as part of a group. Dr. Cooper accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cooper as offering telehealth.

Dmand AI links 20 papers to Dr. Cooper, published from 2012 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Anaplastic Lymphoma Kinase. Dr. Cooper has published most often in JTO Clin Res Rep. Dr. Cooper's most frequent co-authors are Jamie E. Chaft, MD, Mark M. Awad, MD, PhD and Rebecca Suk Heist, MD, MPH.

CMS Open Payments shows 26 general payments to Dr. Cooper from 6 drug and device companies from 2023 to 2025. Consulting fees make up the largest share, 87% of the total. Gilead Sciences, Inc. paid the most, $8,642.

Dr. Cooper graduated from The Warren Alpert Medical School of Brown University in 2017.

Dr. Cooper is in network with 12 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.